Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inebilizumab in advanced B-cell malignancies
NCT00983619Phase 2Completed
- Sponsor
- MedImmune
- Start
- Apr 2010
- Primary completion
- Mar 2019
- Modality
- Monoclonal Antibodies
- Countries
- 5
01
Overview
Phase 2, open-label trial of inebilizumab in B cell malignancies, chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma (DLBCL) and 2 more, sponsored by MedImmune. Primary endpoints: Maximum Tolerated Dose, Treatment-emergent Adverse Events and 8 more. Started Apr 2010; status: completed.
02
Drugs
inebilizumab
03
Conditions
B cell malignancieschronic lymphocytic leukemia (CLL)diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00983619.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00983619.